组织蛋白酶K在慢性肾脏病中的检测意义
|
摘要
目的:探讨组织蛋白酶K(Cathepsins K,CatK)在慢性肾脏病(CKD)中的检测意义。方法:随机抽取2015年7-12月在本院门诊治疗的CKD患者91例(CKD组),根据骨密度测量结果将患者分为三组:骨密度正常组(A组)、骨密度降低组(B组)和骨质疏松(Osteoporosis OP)组(C组)。同时随机选取30例健康人作为对照组。所有对象入院后即抽血查CatK、Cr、BUN、Cys C及PTH等水平。结果:(1)CKD组CatK、Cr、BUN、Cys C及PTH水平均高于对照组,差异有统计学意义(P<0.05);(2)CatK水平C组高于B组及A组,B组高于A组,差异有统计学意义(P<0.05);(3)PTH水平C组高于B组及A组,B组高于A组,差异有统计学意义(P<0.05);(4)CatK与Cr成正相关,相关系数r=0.648(P<0.01);CatK与BUN成正相关,相关系数r=0.488(P<0.01);CatK与Cys C成正相关,相关系数r=0.438(P<0.01);CatK与PTH成正相关,相关系数r=0.294(P<0.01)。结论:检测CatK有助于判断CKD患者并发OP的可能性及严重性;PTH可能对CatK的分泌释放具有调节作用。
Objective:To observe The significance of detection of cathepsins K in chronic kidney disease.Methods:Slecting 91patients(CKD group)with chronic kidney disease and devide 3groups according to the results of bone mineral density measurement:Bone density normal group(A group),Bone mineral density reduction group(B group)and osteoporosis group(C group);slecting 30 healhty persons as the control group.Results:CatK,Cr,BUN,Cys and PTH of CKD groups are higher than control group significance(P<0.05);(2)CatK of C groups are higher than A group and B group,CatK of B groups are higher than A group(P<0.05);(3)PTH of C groups are higher than A group and B group,PTH of B groups are higher than A group(P<0.05);(4)CatK was positively correlated with serum Cr,r=0.648(P<0.01),CatK was positively correlated with serum BUN,r=0.488(P<0.01),CatK was positively correlated with serum Cys C,r=0.438(P<0.01),CatK was positively correlated with serum PTH,r=0.294(P<0.01).Conclusion:Detection of CatK is helpful to judge the possibility of CKD in patients with OP and severity,PTH may regulate the secretion of CatK.
Objective:To observe The significance of detection of cathepsins K in chronic kidney disease.Methods:Slecting 91patients(CKD group)with chronic kidney disease and devide 3groups according to the results of bone mineral density measurement:Bone density normal group(A group),Bone mineral density reduction group(B group)and osteoporosis group(C group);slecting 30 healhty persons as the control group.Results:CatK,Cr,BUN,Cys and PTH of CKD groups are higher than control group significance(P<0.05);(2)CatK of C groups are higher than A group and B group,CatK of B groups are higher than A group(P<0.05);(3)PTH of C groups are higher than A group and B group,PTH of B groups are higher than A group(P<0.05);(4)CatK was positively correlated with serum Cr,r=0.648(P<0.01),CatK was positively correlated with serum BUN,r=0.488(P<0.01),CatK was positively correlated with serum Cys C,r=0.438(P<0.01),CatK was positively correlated with serum PTH,r=0.294(P<0.01).Conclusion:Detection of CatK is helpful to judge the possibility of CKD in patients with OP and severity,PTH may regulate the secretion of CatK.
引文
[1]崔敏,于灵芝.组织蛋白酶K抑制剂Odanacatib的研究进展[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(4):264-268.
[2]Zhao DF,Jiang YF,Dong XY,et al.Aresenic trioxide reduces drug resistance to adriamycin in leukemic K562/A02cells via multiple mechanisms[J].Biomed Pharmacother,2011,65(5):354-358.
[3]郭夏青,卢摇宏.血清组织蛋白酶K、胱抑素水平与缺血性脑血管病患者颈动脉粥样硬化斑块稳定性的关系[J].郑州大学学报:医学版,2013,48(2):269-271.
[4]毛旭东,张汝忠.老年慢性肾功能不全患者的骨密度及骨代谢变化[J].中国骨质疏松杂志,2011,17(4):321-323.
[5]Eddington H,Kalra PA.The association of chronic kidney disease-mineral bone disorder and cardiovascular risk[J].J Ren Care,2010,36(Suppl I):61-67.
[6]中华医学会肾脏病学分会.慢性肾脏病患者骨质疏松治疗[J].中华肾脏病杂志,2014,30(增刊):37-44.
[7]陈翌阳,李新民.老年慢性肾脏病患者骨质疏松发生情况与危险因素[J].临床和实验医学杂志,2014,13(17):1411-1413.
[8]李桂英,肖太玲.慢性肾衰竭与骨质疏松的相关因素分析[J].中国骨质疏松杂志,2011,17(5):405-407.
[9]何伟涛,刘康.组织蛋白酶k与骨质疏松症治疗的研究进展[J].中国骨质疏松杂志,2008,14(9):670-673.
[10]刘红,廖二元.骨钙素与代谢性骨病[J].国外医学内分泌学分册,2004,24(4):239-249.
[11]盛彤,郭翔宇.骨钙素的能量代谢调节作用[J].中华内分泌代谢杂志,2014,30(10):862-864.
[2]Zhao DF,Jiang YF,Dong XY,et al.Aresenic trioxide reduces drug resistance to adriamycin in leukemic K562/A02cells via multiple mechanisms[J].Biomed Pharmacother,2011,65(5):354-358.
[3]郭夏青,卢摇宏.血清组织蛋白酶K、胱抑素水平与缺血性脑血管病患者颈动脉粥样硬化斑块稳定性的关系[J].郑州大学学报:医学版,2013,48(2):269-271.
[4]毛旭东,张汝忠.老年慢性肾功能不全患者的骨密度及骨代谢变化[J].中国骨质疏松杂志,2011,17(4):321-323.
[5]Eddington H,Kalra PA.The association of chronic kidney disease-mineral bone disorder and cardiovascular risk[J].J Ren Care,2010,36(Suppl I):61-67.
[6]中华医学会肾脏病学分会.慢性肾脏病患者骨质疏松治疗[J].中华肾脏病杂志,2014,30(增刊):37-44.
[7]陈翌阳,李新民.老年慢性肾脏病患者骨质疏松发生情况与危险因素[J].临床和实验医学杂志,2014,13(17):1411-1413.
[8]李桂英,肖太玲.慢性肾衰竭与骨质疏松的相关因素分析[J].中国骨质疏松杂志,2011,17(5):405-407.
[9]何伟涛,刘康.组织蛋白酶k与骨质疏松症治疗的研究进展[J].中国骨质疏松杂志,2008,14(9):670-673.
[10]刘红,廖二元.骨钙素与代谢性骨病[J].国外医学内分泌学分册,2004,24(4):239-249.
[11]盛彤,郭翔宇.骨钙素的能量代谢调节作用[J].中华内分泌代谢杂志,2014,30(10):862-864.